6:00 PM – 6:30 PM Dinner and Registration
6:30 PM – 6:45 PM Welcome and Introduction
6:45 PM – 7:15 PM MPN Driver Mutations, Diagnosis, Contemporary Prognostic Assessments, and Risk Stratification: Where Are We Now and Where Are We Headed?
Tumor Board Discussions: Real-World Cases
7:15 PM – 7:55 PM Myelofibrosis: Contemporary Management
7:55 PM – 8:25 PM Myelofibrosis: Managing Patients Intolerant/Resistant to Ruxolitinib and Emerging Strategies
8:25 PM – 9:05 PM Polycythemia Vera and Essential Thrombocythemia in Focus
9:05 PM – 9:30 PM Final Thoughts and Audience Question and Answer Session
Date / Time
Srdan Verstovsek, MD
Division of Cancer Medicine
Department of Leukemia
The University of Texas M. D. Anderson Cancer Center
Jean Jacques Kiladjian, MD, PhD
Department of Clinical Pharmacology
Université de Paris
Clinical Investigations Center
Raajit Rampal, MD
Assistant Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Alessandro Vannucchi, MD
Full Professor of Hematology
Department of Experimental and Clinical Medicine
University of Florence
Center of Research and Innovation of Myeloproliferative Neoplasms
The goal of this activity is to improve participants’ knowledge of and competence in integrating new agents into the treatment of patients with myeloproliferative neoplasms.
This program is intended for physicians and other healthcare providers who treat and manage patients with myeloproliferative neoplasms.
- Select optimal, individualized treatment for patients with MPNs based on recent advances and evolving best practices to maximize clinical outcomes
- Integrate emerging agents and regimens for MPNs into routine practice as clinically appropriate
- Develop an evidence-based treatment plan to improve outcomes in the treatment of MPNs
- Develop strategies to identify and mitigate predictable treatment-related adverse events in a timely fashion
- Refer appropriate patients with MPNs to select ongoing clinical trials of novel agents and strategies
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.